Acura Pharmaceuticals (Acura Pharmaceuticals) Momentum Rank : 0 (As of May. 16, 2024)

View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Momentum Rank?

Acura Pharmaceuticals has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Acura Pharmaceuticals Momentum Rank Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

616 N. North Court, Suite 120, Palatine, IL, USA, 60067

Website

http://www.acurapharm.com

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

Executives

Bruce F Wesson	director	1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly	director	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross	director	1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh	officer: VP, Corporate Development
Immanuel Thangaraj	director	10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser	officer: VP, Treasurer & Controller	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones	officer: President & CEO	C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko	officer: VP Pharmaceutical Sciences APT	C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens	officer: Senior VP & CFO	C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc	10 percent owner	333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc	10 percent owner	C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte	10 percent owner	9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P	10 percent owner	610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc	10 percent owner	680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp	10 percent owner	610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020